What is Pneumocystis jirovecii pneumonia (PJP) prophylaxis?

What is PJP Prophylaxis?

PJP prophylaxis is the use of antimicrobial medications—most commonly trimethoprim-sulfamethoxazole (TMP-SMX)—to prevent Pneumocystis jirovecii pneumonia in immunocompromised patients at risk for this life-threatening opportunistic fungal infection. 1

Core Concept

• Pneumocystis jirovecii is a ubiquitous fungal organism that colonizes healthy respiratory tracts but causes severe pneumonia when cell-mediated immunity is impaired, particularly in patients with compromised T-cell function 1, 2
• Prophylaxis is highly effective and should be given to all patients at moderate to high risk, providing a 91% reduction in PJP occurrence and 83% reduction in PJP-related mortality when TMP-SMX is used 1, 3

Who Requires Prophylaxis

HIV-Infected Patients

• CD4+ count <200 cells/μL or <20% of total T-lymphocytes mandates prophylaxis 1, 3
• Prophylaxis continues until CD4 count >200 cells/μL for at least 3 months 1, 4

Cancer and Hematologic Malignancy Patients

• Acute lymphoblastic leukemia (ALL) patients throughout anti-leukemic therapy 1, 3
• Allogeneic stem cell transplant recipients for at least 6 months post-transplant and while receiving immunosuppressive therapy 1, 3
• Patients receiving alemtuzumab for minimum 2 months after treatment and until CD4 count >200 cells/μL 1, 3
• CAR T-cell therapy recipients for ≥6 months and while receiving immunosuppressive therapy 3
• Patients receiving bispecific antibodies (teclistamab, elranatamab) due to 3.6-4.9% incidence in trials 1, 3
• Temozolomide with radiation therapy during concurrent treatment and until recovery from lymphocytopenia 1, 3

Corticosteroid-Related Risk

• ≥20 mg prednisone (or equivalent) daily for ≥4 weeks is the standard threshold 1, 3
• Methylprednisolone 20 mg IV is approximately equivalent to prednisone 25 mg orally, with the same ≥4 week duration threshold applying 3
• For immune checkpoint inhibitor toxicity, the threshold is >30 mg prednisone daily for >3 weeks, or ≥20 mg methylprednisolone for ≥4 weeks for pneumonitis specifically 3

Rheumatologic and Autoimmune Disease Patients

• Rituximab or cyclophosphamide mandates prophylaxis regardless of steroid dose 3
• Triple immunosuppression (corticosteroids plus cyclophosphamide, or corticosteroids plus thiopurine plus calcineurin inhibitor/infliximab) requires prophylaxis 1
• ANCA-associated vasculitis (GPA/MPA) patients receiving rituximab or cyclophosphamide 3

Solid Organ Transplant Recipients

• Prophylaxis for at least 6-12 months post-transplant in all solid organ recipients 1, 5
• Continue while immunosuppression persists 1

Prophylaxis Regimens

First-Line: TMP-SMX

• Double-strength (800 mg/160 mg) three times weekly (consecutive or non-consecutive days) is the preferred regimen 1, 3
• Alternative dosing: one double-strength tablet daily 1
• TMP-SMX provides additional protection against common bacterial infections, listeriosis, nocardiosis, and toxoplasmosis 3

Alternative Agents (for TMP-SMX intolerance)

Atovaquone:

• 1500 mg orally daily 1, 4
• Must be taken with food to increase bioavailability 1.4-fold; failure to do so may result in subtherapeutic levels and prophylaxis failure 4
• Offers convenience of oral daily dosing without hematologic monitoring 4
• Does not provide additional bacterial protection that TMP-SMX offers 4

Dapsone:

• 100 mg orally daily 1, 4
• Requires G6PD testing before initiation to prevent life-threatening hemolysis 1, 4
• Requires monitoring for methemoglobinemia 4

Aerosolized Pentamidine:

• 300 mg monthly via Respirgard II nebulizer 1, 4
• Requires monthly healthcare visits 4
• Contraindicated in patients with prior pentamidine-related hypoglycemia, pancreatitis, cardiac arrhythmia, or severe hypotension 1
• Administer two puffs of albuterol (100 µg each) 10 minutes before pentamidine to prevent bronchospasm 1

Duration of Prophylaxis

• HIV patients: Until CD4 count >200 cells/μL for at least 3 months 1, 4
• Transplant recipients: At least 6-12 months post-transplantation 1, 4, 5
• Corticosteroid users: While receiving ≥20 mg prednisone daily or equivalent 3, 4
• Rituximab recipients: For at least 6 months after the last dose 3
• All other immunocompromised patients: For the duration of immunosuppression 1, 4

Critical Pitfalls to Avoid

• Never discontinue TMP-SMX prophylaxis solely because a patient is receiving broad-spectrum antibiotics for sepsis—vancomycin and piperacillin-tazobactam do not provide PCP coverage 1
• Always check G6PD levels before using primaquine or dapsone to prevent life-threatening hemolysis 1, 4
• Monitor for severe cytopenia when combining TMP-SMX with methotrexate—this combination increases risk of severe bone marrow suppression 1, 3
• Do not rely on CD4+ counts alone in non-HIV immunocompromised patients—many develop PJP with counts >200 cells/μL 3
• Ensure atovaquone is taken with food—fasting administration results in subtherapeutic levels 4
• Do not delay prophylaxis in high-risk patients—PJP carries a 35% mortality rate within 2 months in untreated populations 3

Renal Dosing Adjustments

• CrCl 15-30 mL/min: Halve the prophylactic TMP-SMX dose 1
• CrCl <15 mL/min: Use half-dose or switch to alternative agent 1